Octave at MSMilan2023!
Wednesday, Oct. 11 – Friday, Oct. 13
Milan, Italy
Connect with us through several events to learn how we are changing the paradigm of care in multiple sclerosis (MS)!
Product Theatre
Delivering on the Promise of Precision Medicine: Lessons Learned Through Real-World Clinical Experience
Friday, Oct. 13
11:40 – 12:00 CEST
Product Theatre Stage, Exhibit Hall on Level 0
Join us for a discussion on precision care with:
- Barry Singer, MD Director and Founder of The MS Center for Innovations in Care at Missouri Baptist Medical Center and Associate Professor of Clinical Neurology at Washington University School of Medicine
- Mitzi Joi Williams, MD, FAAN Medical Director, Joi Life Wellness Neurology Group
- Julie Burnham, DO, President/Owner Michigan Neurology
- Michael Sy, MD, PhD Associate Professor of Clinical Neurology, Department of Neurology, University of California, Irvine
Octave Product Theater at ECTRIMS 2022.
Catch a glimpse of what you can expect at MSMilan 2023 from one of the panelists presenting at ACTRIMS 2023
Brain Exchange
Optimization of Advanced Imaging Biomarkers for Objective Decision-Support in MS: From Research to the Real World
Friday, Oct. 13
13:40 – 14:10 CEST
Industry Theater, Exhibit Hall on Level 0
- Kelly Leyden, Senior Product Lead – MRI Insights, Octave
- Jennifer Graves, MD, PhD, MAS, UCSD Director of Neuro-immunology Research Professor of Neurosciences Director, Rady Pediatric MS Center
Booth & Meetings
Visit us at booth #D42
Visit us at booth #D42 to learn about Octave’s Precision Care Solution which includes the first-and-only multivariate blood test to measure MS Disease Activity, enhanced MRI analytics and protocols, and a clinical care program that tracks and connects patients with MS nurse practitioners in real time.
Posters
Wednesday, Oct. 11 | 16:30 – 18:30 CEST | Gold Room
- Biology – Serum Biomarkers of Clinical and Radiographic Disease Progression in Multiple Sclerosis
- Biology – Real-World Utilization of a Proteomic Biomarker Panel for Assessing Multiple Sclerosis Disease Activity in an Academic Multiple Sclerosis Clinic with a Diverse Patient Population
- Biology – CXCL-13, CXCL-9 and IL-12 cerebrospinal fluid levels predict higher disease activity and are associated with intrathecal IgM synthesis in multiple sclerosis
- Biology – Compartmentalized complement activation is associated with cytokines CXCL-13, CXCL-9, Il-12b and paramagnetic rim lesions in multiple sclerosis
- Imaging – Disagreement Among Neuroradiologists Detecting Change in Multiple Sclerosis Disease Activity
- Imaging – Interpretable Thalamic Volume Charts in Multiple Sclerosis
Thursday, Oct. 12 | 17:00 – 19:00 CEST | Gold Room
- Biology – Disease Activity Score and Disease Pathway Scores Measured Using the MSDA Test are Significantly Reduced Prior to the Week 48 Dose for Patients Treated with Ublituximab in the Phase 3 ULTIMATE I and II Studies
- Biology – Lower arterial cerebral blood flow is associated with worse neuroinflammation and immunomodulation composite proteomic scores